Leaders in Pharmaceutical Business Intelligence (LPBI) Group

LPBI Group’s Vision is dynamically undated at the following LINKS:

 

2019 Strategic Marketing of LPBI Group’s Intellectual Property: Strength & Markets

https://pharmaceuticalintelligence.com/vision/2019-strategic-marketing-of-lpbi-groups-intellectual-property-strength-markets/

 

TO BE UPDATED on 1/5/2019

https://pharmaceuticalintelligence.com/gama-delta-epsilon-gde-is-a-global-holding-company-absorbing-lpbi/

https://pharmaceuticalintelligence.com/gde-news/

https://pharmaceuticalintelligence.com/calendar/

 

 

 

LPBI Group has Three Enterprise Types and Five Subsidiaries

We are in the Professional Services Sector: e-Scientific Information Creation and Intellectual Property Assets Management:

 

Subsidiary #1: electronic Scientific Media or Scientific Digital Media – LPBI

and

Subsidiary #4: We are intermediaries for Commercialization, Licensing, Sales Outright of US Patents, representing Two inventors in Medical Devices

We are in Research Biotech Businesses

 

Subsidiary #3: R&D in 3D BioPrinting

FUNDING needs: $20Million [If VAR considered: $40Million]

and

Subsidiary #5: R&D in Drug Discovery

FUNDING needs: $20Million

We are in the Financial Transaction Sector (No Securities Traded):

 

Subsidiary #2: Deals, Funding and Partnerships

• MEDICAL DEVICES
• Informational PLATFORMS
• INVENTIONS IN BIOLOGICS

 

 

In Preparation: VB Profile

http://pages.vbprofiles.com/TheMostPopularLists

 

LPBI Group runs by:

Aviva Lev-Ari, PhD, RN – Founder of e-Scientific Media Enterprise (2012) and the LPBI Group (2016)

CORE VALUES

Leadership quality of our Team members:

Straightforward and Transparent, Honest and Trustworthy, Ethical and Principled, Authentic, Focused, Determined, Realistic, Decisive and Action-oriented, Accountable, Fair and Open-minded, Knowledgeable and Experienced, Consistent and Dependable, Confident and Optimistic, Insightful, discerning, Passionate, Empathetic and Selfless, Flexible, Humble, Courageous, Reciprocity, Hardworking.

Since LPBI Group’s IP is unencumbered, commercialization of US Patents is rendered to Funding rather than to litigation. Our Platform is accessible only to members of the Team in the Three Enterprise Type consisting of five subsidiaries that follow our Core values: 

• deep Expertise  
• shake of hand instead of 21 page contracts
• venture wellbeing comes first, personnel wellbeing is derived only from a healthy venture
• full transparency with the Team and with Investors
• loyalty to Management, to each Team member and daily adherence to Business Etiquette 
• Team Playing is key — pushing back is not acceptable

STRATEGIC PLAN for LPBI Group (Draft)

https://pharmaceuticalintelligence.com/gama-delta-epsilon-gde-is-a-global-holding-company-absorbing-lpbi/2016-strategic-plan-for-gde-enterprises/

 

What’s Part of LPBI Group?

MATERIAL BELOW THIS POINT IS UNDER CONSTRUCTION

HIGHLIGHTS

Subsidiary #1: Leaders in Pharmaceutical Business Intelligence

Scientific Digital Media

LPBI

• Open Access Online Scientific Journal – IP by Our Team

http://pharmaceuticalintelligence.com

• e-Books: WE ARE ON AMAZON.COM – IP by Our Team

http://www.amazon.com/dp/B00DINFFYC

http://www.amazon.com/dp/B018Q5MCN8

http://www.amazon.com/dp/B018PNHJ84

http://www.amazon.com/dp/B018DHBUO6

http://www.amazon.com/dp/B013RVYR2K

http://www.amazon.com/dp/B012BB0ZF0

http://www.amazon.com/dp/B019UM909A 

http://www.amazon.com/dp/B019VH97LU

• Biotech Conferences – Real Time Press Coverage of Biotech and Medicine Conferences

IP by Aviva and Dr. Williams.

By 12/2016 will be a candidate to consider M&A

Subsidiary #2: Deals, Funding & Partnerships

DFP

Funding Early Stage Biotech: IP by others

• Biologics or
• Medical Devices.

Average investment needed per venture $10Million and above

Subsidiary #3: Medical 3D BioPrinting

M3DP

Team of 15 – IP by Our Team

• Aviva manages R&D by the Team creating IP for a Pipeline of Medical Applications using 3D BioPrinting in two specialty departments: 

1. R&D in Tissue Engineering, Gene Therapy: Stem Cells and Gene Editing and Drug dosing and printing
2. R&D in BioMEMS, Programmable Sensors and Medical Devices

• Gerard manages development of VARS of BioPrinters and BioInks

Funding needs: $20Million

Subsidiary #4: U.S. and Int’l Patents – Commercialization, Licensing and Sales  

USPat

IP by Patent Holders

• Funding needed to commercialize,
• Partnerships to license
• Buyers for Sales of IP of Two Team members:

(a) to “corporate accounts”

(b) to “IP and Technology Patents Fund Managers”

Subsidiary #5: Joint Ventures for Intellectual Property Development

JVIP

SBH & M3DP (same Team as Subsidiary #3) – IP by Our Team

• Aviva manages R&D conducted by these two organizations created by a collaborative effort, creation of a pipeline of product concepts 
• Seeking Funding of  $20Milllion